MarketPulse

cancer diagnostics

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Precipio Enhances Shareholder Engagement With First Live Q&A Session

Precipio adds live Q&A to Q1-2026 earnings call on May 18th, signaling enhanced commitment to shareholder transparency and investor engagement in specialty diagnostics.
PRPOcancer diagnosticsQ&A session
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Oncology Biomarkers Market to Double by 2030 as AI, Liquid Biopsies Drive Growth

Global oncology biomarkers market projected to grow from $17.3B (2025) to $33.63B (2030) at 14.3% CAGR, driven by AI, liquid biopsies, and precision medicine adoption.
NVSILMNRHHBYTMOGHpersonalized medicinecancer diagnostics
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Precipio Posts 30% Revenue Growth; Partners with Memorial Sloan-Kettering on Cancer Test

Cancer diagnostics firm $PRPO reports $24M in 2025 revenues, up 30% year-over-year, and publishes peer-reviewed study on its BCR::ABL1 blood test.
PRPOQ4 2025 earningsrevenue growth
The Motley FoolThe Motley Fool··James Halley

Telix Pharmaceuticals Eyes Growth With Nuclear Medicine Expansion

Telix Pharmaceuticals expands its nuclear medicine presence with approved cancer-targeting drugs and 56% revenue growth, positioning itself as a key player in oncology diagnostics and therapeutics.
TLXbiotechradiopharmaceuticals
The Motley FoolThe Motley Fool··James Halley

Abbott Laboratories Positions as Dividend Growth Play Amid Diagnostic Headwinds

Abbott maintains 54-year dividend streak with 10% EPS growth projected for 2026, despite near-term diagnostic headwinds and manufacturing challenges offsetting strategic acquisitions and FDA approvals.
ABTEXASTLRYacquisitionhealthcare